Printed From:

MyStar DoseCoach ®

A first-in-class device designed to simplify insulin therapy management for you and your patients. MyStar DoseCoach helps your patients to self-adjust their insulin glargine dose, according to your instructions.

Training video

Key Features

Safety

MyStar DoseCoach’s Dose Helper function is based on well-accepted treat-to-target approaches for dose adjustment of basal insulin glargine 1-6 and is supervised by built-in safety and verification rules.

Individualised for each patient

Three treatment plans to choose from, based on your patients' basal insulin therapy needs.

Support

MyStar DoseCoach simplifies insulin glargine dose adjustment, and may help you to optimise your patients' diabetes therapy.

Specifications
Specification Description
Coding No code
Sample size 0.5 microliters
Average glucose test time 5 seconds
Assay method Dynamic Electrochemistry
Memory Stores the last 1000 glucose records, including control solution and blood results Stores the last 90 hypo events Stores the last 180 Dose Helper dose suggestions and last 180 confirmed doses taken
Alarms Programmable dose reminder alarm
Measurement units mg/dL or mmol/L (preset to the standard unit generally used in country where the meter was purchased. The user cannot change the unit of measurement setting)
Maximum altitude 3,048 m (10,000 ft)
Hematocrit 20% to 60%
Operating relative humidity 25% to 90%
Operating temperature 10°C to 40°C (50°F to 104°F)
Calibration Plasma equivalent
Result range 1.1 to 33.3 mmol/L, 20 to 600 mg/dL
Size L = 110 mm, W = 60 mm, H = 25 mm
Weight 100 g (3.5oz) including batteries
Power source Two replaceable, primary (non-rechargeable) AA lithium batteries and one non-replaceable coin cell battery (CR2032)
Automatic deactivation 1 minute of inactivity unless an error message is displayed, dead battery message is displayed, BG measurement sequence is active or meter connected to an active USB cable
4 minutes of inactivity if BG measurement sequence is active, an error message is displayed or meter is connected to an active USB cable
7 seconds of inactivity after dead battery message is displayed

Meet MyStar DoseCoach

A first-in-class device designed to support your patients’ day-to-day insulin management at home

Individualise patient therapy with MyStar DoseCoach

The three available activation keys allow you to select the most appropriate treatment plan for your patient. The plan can be further individualised by adding information such as body weight, insulin glargine starting dose and usual dose time.

Training

Setting up MyStar DoseCoach

FAQ

What is MyStar DoseCoach?

  • MyStar DoseCoach is a first of its kind device integrating both an insulin glargine dose helper function and a blood glucose meter. It has been designed to help people with type 2 diabetes to self-adjust their insulin glargine dose according to titration instructions pre-set by their doctor. With its built-in automated insulin advisory system, MyStar DoseCoach provides type 2 diabetes patients with reassurance for their daily basal insulin dose selections and simplifies insulin management between doctor visits.

How does MyStar DoseCoach work?

  • Dose Helper activation
    • You need to activate MyStar DoseCoach’s Dose Helper function by selecting one of the three available treatment plans according to your patients’ basal insulin therapy needs. You can further personalize the device for your patients by entering patient-specific parameters such as patient body weight, insulin glargine starting dose, and usual dose time.
  • Dose suggestions
    • Once MyStar DoseCoach’s Dose Helper function is activated, users need to record their fasting blood glucose readings and insulin glargine doses during the first 3 days in order for Dose Helper to provide the first dose suggestion on the fourth day.
    • Dose Helper will continue to make daily insulin glargine dose suggestions based on, and adjusted to, the most recent fasting blood glucose readings, current insulin glargine dose, and occurrence of any hypoglycemic events.

References

  1. Davies M, et al. A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes. J Diabetes Sci Technol. 2019 Jan 15:1932296818821706. doi: 10.1177/1932296818821706. [Epub ahead of print].
  2. American Diabetes Association. Standards of Medical Care in diabetes. Diabetes Care 2019. Jan 2019; 42 (Supplement 1) S1-S2.
  3. Hirsch I, et al. A Real-World Approach to Insulin Therapy in Primary Care Practice. Clinical Diabetes 2005;23(2):78-86.
  4. Nathan D, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy; a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203.
  5. Inzucchi S, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2015;38:140-149.
  6. Handelsman Y, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 2015;21(Suppl1):1-87.